Story perspectives

Supreme Court Upholds Medicare Drug Negotiations, Expands to 40

5/18/2026

Summary

Story summary

U.S. Supreme Court rejected appeals on Monday, leaving the Medicare drug-price negotiation program intact.
The 2022 Inflation Reduction Act-mandated program, which has cut prices for 25 drugs including Ozempic, Rybelsus and Wegovy, will be expanded by President Donald Trump’s administration, adding 15 more drugs to reach 40.
Pharmaceutical firms say reductions should come from regulating insurers and pharmacy-benefit managers and note Congress can end the program, which has no expiration.

1 of 1

Story summary

U.S. Supreme Court rejected appeals on Monday, leaving the Medicare drug-price negotiation program intact.
The 2022 Inflation Reduction Act-mandated program, which has cut prices for 25 drugs including Ozempic, Rybelsus and Wegovy, will be expanded by President Donald Trump’s administration, adding 15 more drugs to reach 40.
Pharmaceutical firms say reductions should come from regulating insurers and pharmacy-benefit managers and note Congress can end the program, which has no expiration.